Videos

Advancing Gene Therapies for Rare Diseases: Implementing Novel Strategies for Not-For-Profit Innovation

Rome, April 16, 2025

Alliance for Regenerative Medicine’s 2025 Cell and Gene Meeting on the Med

Our CEO John W. Hadden II was honored to moderate these accomplished panelists:

Hilary Eaton, PhD, Chief Business Officer, Profluent.bio

Sadik Kassim, PhD, Chief Scientific Officer and Chief Technology Officer, Danaher Genomic Medicines

Maryam Mokhtarzadeh, MD, Senior Director, Regulatory Strategy, REGENXBIO

Hilary Schultz, CEO and Founder, Persephoni BioPartners